The present invention concerns compounds and their use to treat cardiovascular disease, renal disease, thrombic disease, stroke, metabolic syndrome, cell proliferation, and ischemic cardiovascular disorders. Compounds of the present invention display significant potency as antagonists of 20-hydroxyeicosatetraenoic acid (20-HETE), and function as anti-hypertensive, anti-inflammatory, or anti-growth agents.

This disclosure provides multifunctional conjugate molecules in which at least one therapeutic agent is covalently attached to a cannabinoid. The disclosed conjugate molecules are designed to deliver therapeutic benefits of both components, with release of the cannabinoid upon binding of the therapeutic agent component to its target conveying further therapeutic benefits, and can be used to treat cancer, glaucoma, confusion or dementia, and other disorders.

A class of compounds useful in pharmaceutical compositions and methods for treating or preventing cancer is described. Analogs of Mycalolide B have been prepared and tested in breast and ovarian cancer cell lines. The compounds show utility for inhibition of survival and proliferation of tumor cells. The compounds have been shown to disrupt actin.

A class of compounds useful in pharmaceutical compositions and methods for treating or preventing cancer is described. Analogs of Mycalolide B have been prepared and tested in breast and ovarian cancer cell lines. The compounds show utility for inhibition of survival and proliferation of tumor cells. The compounds have been shown to disrupt actin.

Provided are a novel pseudoceramide compound and uses thereof. The pseudoceramide has antioxidant, anti-inflammatory, skin whitening, and moisturizing effects. In addition, the pseudoceramide can be synthesized in a simple and economically advantageous manner and is free from problems associated with the preparation of cosmetic formulations resulting from low hydrophilicity, thus being suitable for use in cosmetic applications.

Provided are a novel pseudoceramide compound and uses thereof. The pseudoceramide has antioxidant, anti-inflammatory, skin whitening, and moisturizing effects. In addition, the pseudoceramide can be synthesized in a simple and economically advantageous manner and is free from problems associated with the preparation of cosmetic formulations resulting from low hydrophilicity, thus being suitable for use in cosmetic applications.

The present invention relates to a compound inhibiting HF-1 activity, a preparation method of the same, and a pharmaceutical composition comprising the same as an active ingredient. The compound of the present invention demonstrates anticancer activity not by non-selective cytotoxicity but by inhibiting the activity of HIF-1, the transcription factor playing an important role in cancer cell growth and metastasis.

Accordingly, the compound or the pharmaceutically acceptable salt thereof according to the present invention inhibits HIF-1 activity, and therefore can be used as a therapeutic agent for solid tumors such as colon cancer, liver cancer, stomach cancer and breast cancer. In addition, the compound or the pharmaceutically acceptable salt thereof according to the present invention can be used as an active ingredient for a therapeutic agent for diabetic retinopathy or arthritis which may become worse when hypoxia-induced VEGF expression by HIF-1 increases.

An N-acylglucamide compound of the formula (I)

##STR00001## where R.sub.2 is a linear or branched alkyl group or an aryl group; X is a moiety R.sub.1, which is a linear or branched alkyl group comprising 8 to 18, carbon atoms, which is substituted by one hydroxy group; or X is a moiety R.sub.1, which is a linear or branched, mono- or polyunsaturated alkenyl group comprising 8 to 18 carbon atoms, which is substituted by one hydroxy group, And blends and aqueous surfactant solutions comprising it.

An N-acylglucamide compound of the formula (I)

##STR00001## where R.sub.2 is a linear or branched alkyl group or an aryl group; X is a moiety R.sub.1, which is a linear or branched alkyl group comprising 8 to 18, carbon atoms, which is substituted by one hydroxy group; or X is a moiety R.sub.1, which is a linear or branched, mono- or polyunsaturated alkenyl group comprising 8 to 18 carbon atoms, which is substituted by one hydroxy group, And blends and aqueous surfactant solutions comprising it.

An N-acylglucamide compound of the formula (I)

##STR00001## where R.sub.2 is a linear or branched alkyl group or an aryl group; X is a moiety R.sub.1, which is a linear or branched alkyl group comprising 8 to 18, carbon atoms, which is substituted by one hydroxy group; or X is a moiety R.sub.1, which is a linear or branched, mono- or polyunsaturated alkenyl group comprising 8 to 18 carbon atoms, which is substituted by one hydroxy group, And blends and aqueous surfactant solutions comprising it.